<DOC>
	<DOCNO>NCT02182102</DOCNO>
	<brief_summary>The primary objective determine safety , tolerability maximum tolerate dose ( MTD ) BIBF 1120 combination pemetrexed . Secondary objective characterize pharmacokinetic profile BIBF 1120 pemetrexed obtain preliminary anti-tumour efficacy information .</brief_summary>
	<brief_title>Dose Escalation BIBF 1120 Combined With Pemetrexed Advanced Non Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Nintedanib</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Pathologic confirmation metastatic , unresectable , locally advanced NSCLC ( nonsmall cell lung cancer ) Disease progression follow one prior platinumbased ( include prior neoadjuvant adjuvant therapy ) chemotherapy regimen advance disease Bidimensionally measurable disease one technique ( CT ( compute tomography ) , MRI ( magnetic resonance imaging ) , Xray ) Age 18 year old Life expectancy least three ( 3 ) month Eastern Cooperative Oncology Group ( ECOG ) performance score 02 Written inform consent consistent ICHGCP ( International Conference Harmonization Good Clinical Practice ) guideline Participation another clinical study within past 28 day prior start therapy concomitantly study Treatment NSCLC ( except radiotherapy palliative reason ) within past 28 day prior Treatment Day 1 trial . All toxicity previous therapy must resolve baseline prior Treatment Day 1 Patient receive one prior chemotherapy regimen advance disease Radiotherapy area measurable disease ( unless disease progression document follow completion therapy ) Patients unwilling unable take folic acid vitamin B12 supplementation Radiotherapy within 4 week prior Treatment Day 1 Prior treatment agent target vascular endothelial growth factor ( VEGF ) pathway , include monoclonal antibody therapy ( bevacizumab ) tyrosine kinase inhibitor Active brain metastasis ( stable &lt; 28 day , symptomatic , require concurrent steroid antiepileptic therapy ) . Patients receive prior whole brain irradiation whose brain metastases stable accord criterion exclude Centrally locate tumor radiologic evidence ( CT MRI ) local invasion major blood vessel , exception tumor receive prior irradiation stable Cavitary necrotic tumor Sanguinous pleural effusion due disease pericardial effusion suspicious disease Other active malignancy diagnose within past 3 year ( nonmelanomatous skin cancer ) Gastrointestinal abnormality would interfere intake absorption ( exception patient gastric esophageal reflux disease control proton pump inhibitor ) study drug , requirement intravenous alimentation , prior surgical procedure affect absorption , treatment peptic ulcer disease within last 6 month , active gastrointestinal bleeding unrelated cancer ( evidence either hematemesis , hematochezia , melena past 3 month without endoscopic document resolution ) , malabsorption syndrome Significant cardiovascular disease ( i.e. , uncontrolled hypertension , myocardial infarction within 6 month , unstable angina , serious cardiac arrhythmia , &gt; 2 New York Heart Association ( NYHA ) Grade 2 congestive heart failure ) History hemorrhagic thrombotic event ( include transient ischemic attack ) past 12 month clinically significant hemoptysis past 3 month Patients receive anticoagulant therapy ( include coumadin , heparin , low molecular weight heparin , aspirin Patient receive prior therapy pemetrexed Absolute neutrophil count ( ANC ) ≤1,500/μl , platelet count ≤100,000/μl , hemoglobin &lt; 9 gm/dL Total bilirubin &gt; 1.5 mg/dL ( 26 μmole/L , SIUnit equivalent ) , alanine amino transferase ( ALT ) and/or aspartate amino transferase ( AST ) ≥1.5 X upper limit normal ( ULN ) Inadequate renal function determine serum creatinine level &gt; 1.5 X ULN Patient unable unwilling interrupt aspirin NSAIDS 5day period ( 8 day period long lasting agent like piroxicam ) Persistent hematuria proteinuria ( trace ) Women men sexually active unwilling use medically acceptable method contraception Pregnancy breast feed Known suspect active alcohol drug abuse Patients unable comply protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>